Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced the appointment of Eran Kuratz as head of supply chain and business process administration for its wholly owned subsidiary, Scinai Biopharma Services Ltd. This strategic move is designed to bolster the company's contract development and manufacturing organization (CDMO) platform, which has recently expanded significantly.
Kuratz brings over 30 years of leadership experience in supply chain and operations across the pharmaceutical, biotechnology, medical-device, and industrial sectors. In his new role, he will oversee procurement, contracting, inventory management, logistics, budgeting, IT and business systems, cybersecurity, and cross-functional business processes. His appointment is expected to enhance operational efficiency and support the company's growth trajectory.
The appointment comes on the heels of Scinai's expansion of its CDMO platform through the acquisition of Recipharm Israel, which is slated to close in the first quarter of 2026. This acquisition adds a second development and manufacturing site in Yavne, Israel, complementing the company's existing operations in Jerusalem. The combined facilities will offer a comprehensive range of services, including biologics process development, aseptic manufacturing, sterile fill-and-finish, small-molecule active pharmaceutical ingredient (API) development and synthesis, analytical-method development, and GMP manufacturing.
This expansion positions Scinai to better serve biotechnology and pharmaceutical companies seeking high-quality development and manufacturing services. The company's enhanced capabilities are particularly relevant as the demand for contract manufacturing in the biopharmaceutical industry continues to rise.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. The company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. In addition to its CDMO services, Scinai is dedicated to addressing unmet medical needs in immunology.
For more information about Scinai Immunotherapeutics and its latest updates, visit the company's newsroom at https://ibn.fm/SCNI.
